By reprogramming immune cells and increasing the expression of PD-L1 on tumor cells, HDAC6 inhibition enhances the antitumor activity of CD8 + T cells and amplifies immune responses, creating a more favorable tumor microenvironment [197]. Here, HDAC6 is linked to neoplasm.